CXCR2/CXCL2信号通路:高级别胶质瘤的替代治疗策略
该研究在GL261荷瘤小鼠中探讨CXCR2及其配体CXCL2/CXCL8在胶质瘤血管生成中的作用,并评估CXCR2拮抗剂SB225002的疗效。早期和延迟局部治疗均使胶质瘤体积缩小约50%,伴血管密度降低和微胶质/巨噬细胞积聚,VEGF相关基因未受影响。提示CXCR2/CXCL2通路是胶质瘤有前景的治疗靶点。
要点
- CXCR2拮抗剂局部治疗使胶质瘤体积缩小约50%。
- 治疗降低血管密度并增强髓系细胞与肿瘤血管的相互作用。
- CXCR2/CXCL2通路可作为抗血管生成的替代靶点。
核心结论
- CXCR2拮抗剂在肿瘤起始和进展期均抑制胶质瘤生长,且受体耐受良好。
- CXCR2/CXCL2信号通路是胶质瘤有前景的治疗靶点。
研究设计与样本
- 将GL261胶质瘤细胞颅内植入同系小鼠。
- 局部或全身使用CXCR2拮抗剂SB225002治疗14天或7天,于接种当天早期开始或肿瘤生长14天后延迟开始。
- 治疗前后用MRI验证胶质瘤体积,并用免疫荧光染色评估肿瘤进展、血管生成和微胶质细胞行为。
- 进行体外实验和基因表达分析以验证抑制剂活性。
主要发现
- 早期和延迟局部治疗均使胶质瘤体积显著缩小约50%。
- 治疗组与对照组在侵袭性、增殖和凋亡细胞活性方面相当。
- CXCR2/CXCL2表达未见差异。
- 免疫染色显示血管密度降低、微胶质/巨噬细胞积聚,且这些髓系细胞与肿瘤血管的相互作用增强。
- 体外高浓度SB225002直接抑制胶质瘤和内皮细胞增殖;SB225002增加两种细胞中CXCR2/CXCL2信号基因表达,但VEGF相关基因未受影响。
临床怎么用
- CXCR2/CXCL2通路可作为高级别胶质瘤抗血管生成的替代治疗靶点。
- CXCR2拮抗剂局部给药在肿瘤早期和进展期均显示抑瘤活性且耐受良好。
局限性
- 研究基于GL261同系小鼠模型,尚未在人体中验证。
- 体外抑制细胞增殖需较高浓度SB225002,与体内有效浓度的相关性未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Besides VEGF, alternative signalling via CXCR2 and its ligands CXCL2/CXCL8 is a crucial part of angiogenesis in glioblastoma. Our aim was to understand the role of CXCR2 for glioma biology and elucidate the therapeutic potential of its specific inhibition. METHODS: GL261 glioma cells were implanted intracranially in syngeneic mice. The 14 or 7 days of local or systemic treatment with CXCR2-antagonist (SB225002) was initiated early on the day of tumour cell implantation or delayed after 14 days of tumour growth. Glioma volume was verified using MRI before and after treatment. Immunofluorescence staining was used to investigate tumour progression, angiogenesis and microglial behaviour. Furthermore, in vitro assays and gene expression analyses of glioma and endothelial cells were performed to validate inhibitor activity. RESULTS: CXCR2-blocking led to significantly reduced glioma volumes of around 50% after early and delayed local treatments. The treated tumours were comparable with controls regarding invasiveness, proliferation and apoptotic cell activity. Furthermore, no differences in CXCR2/CXCL2 expression were observed. However, immunostaining revealed reduction in vessel density and accumulation of microglia/macrophages, whereas interaction of these myeloid cells with tumour vessels was enhanced. In vitro analyses of the CXCR2-antagonist showed its direct impact on proliferation of glioma and endothelial cells if used at higher concentrations. In addition, expression of CXCR2/CXCL2 signalling genes was increased in both cell types by SB225002, but VEGF-relevant genes were unaffected. CONCLUSION: The CXCR2-antagonist inhibited glioma growth during tumour initiation and progression, whereas treatment was well-tolerated by the recipients. Thus, the CXCR2/CXCL2 signalling represents a promising therapeutic target in glioma.
引用
- Acker G, Zollfrank J, Jelgersma C, et al. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma. Eur J Cancer. 2020. PMID: 31927212. doi:10.1016/j.ejca.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。